ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs that will dramatically extend and improve the lives of patients in areas of high unmet need.With four internally discovered drugs in multiple biomarker guided clinical trials and an enriched proprietary kinase library from which to select additional drug candidates, ArQule is delivering on the potential of precision medicine by providing its patients with novel therapies for multiple hard to treat indications and its shareholders with a focused, highly efficient and cost effective research and development strategy. ArQule is led by a senior management team with significant clinical and commercial expertise that provides the leadership required to optimize its opportunities for success in a rapidly changing and highly competitive field. Source
No articles found.
Aspyron Inc is development stage company that will be completing preparations for ...
Aspyron Inc is development stage company that w...
Developing flexible and affordable genetic testing that improves the everyday live...
Developing flexible and affordable genetic test...
Protagonist Therapeutics is a clinical stage biopharmaceutical company that utiliz...
Protagonist Therapeutics is a clinical stage bi...
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...
Dynavax Technologies Corporation (Nasdaq: DVAX)...
ZBP is a biopharmaceutical company that has developed a proprietary technology to ...
ZBP is a biopharmaceutical company that has dev...
Inovio is bringing IMMUNO-INGENUITY⢠to life and is reshaping the future of trea...
Inovio is bringing IMMUNO-INGENUITY⢠to life ...
Aravive is developing treatments designed to halt progression of life-threatening ...
Aravive is developing treatments designed to ha...
Join the National Investor Network and get the latest information with your interests in mind.